Literature DB >> 8320025

Tumor necrosis factor: status in reactions in leprosy before and after treatment.

S N Bhattacharya1, D Chattopadhaya, K Saha.   

Abstract

BACKGROUND: Tumor necrosis factor-alpha (TNF) is an important mediator of immunologic responses to chronic infections.
METHOD: Sera from 25 patients with acute reactions (6 with type 1 upgrading, 8 with type 1 downgrading, and 11 with type 2 reaction) were assayed for TNF before treatment and after clinical remission of the acute episode. The results were compared with serum TNF levels in healthy controls and fresh pauci- and multibacillary leprosy patients.
RESULTS: TNF levels in acute reactions were higher than in the control groups (significant only in upgrading reaction). In type 1 reaction, serum TNF concentrations fell to approximately the levels of the control patients following treatment and clinical remission. In type 2 reaction, however, levels of TNF were seen to rise further (became statistically significant) as a result of therapy induced clinical remission.
CONCLUSIONS: The rise in TNF-alpha level in reactions in leprosy is significant and indicates its active role in immunopathogenesis. The corresponding decline in TNF-alpha levels seen following regression of type 1 (lepra) reactions was not observed in the case of type 2 (ENL) reaction. This probably reflects the enhancement of cellular immunity in such cases and/or an attempt by the immunologic process to overcome specific inhibitors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320025     DOI: 10.1111/j.1365-4362.1993.tb02816.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

1.  Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions.

Authors:  Anna K Andersson; MeherVani Chaduvula; Sara E Atkinson; Saroj Khanolkar-Young; Suman Jain; Lavanya Suneetha; Sujai Suneetha; Diana N J Lockwood
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

2.  Predicting neuropathy and reactions in leprosy at diagnosis and before incident events-results from the INFIR cohort study.

Authors:  W Cairns S Smith; Peter G Nicholls; Loretta Das; Pramila Barkataki; Sujai Suneetha; Lavanya Suneetha; Rupendra Jadhav; P S S Sundar Rao; Einar P Wilder-Smith; Diana N J Lockwood; Wim H van Brakel
Journal:  PLoS Negl Trop Dis       Date:  2009-08-11

3.  Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.

Authors:  A Iyer; M Hatta; R Usman; S Luiten; L Oskam; W Faber; A Geluk; P Das
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

4.  Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.

Authors:  Mariane M Stefani; Jackeline G Guerra; Ana Lucia M Sousa; Mauricio B Costa; Maria Leide W Oliveira; Celina T Martelli; David M Scollard
Journal:  BMC Infect Dis       Date:  2009-05-27       Impact factor: 3.090

Review 5.  Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy.

Authors:  José Augusto da Costa Nery; Fred Bernardes Filho; Juliana Quintanilha; Alice Miranda Machado; Soraya de Souza Chantre Oliveira; Anna Maria Sales
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

Review 6.  A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.

Authors:  Anastasia Polycarpou; Stephen L Walker; Diana N J Lockwood
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.